Stocksigma LogoStocksigma Logo

Kilitch Drugs to Divest Ethiopian Subsidiary Stake for USD 12.86M via EGM Approval

Kilitch Drugs (India) Ltd. has convened an EGM on 16th Nov'26 to approve the divestment of its entire stake in Ethiopian subsidiary, Kilitch Estro Biotech

Kilitch Drugs to Divest Ethiopian Subsidiary Stake for USD 12.86M via EGM Approval

Kilitch Drugs India Ltd 路 Extra Ordinary General Meeting 路 23 Oct 2026, 10:45 pm

Kilitch Drugs to Divest Ethiopian Subsidiary Stake for USD 12.86M via EGM Approval Kilitch Drugs (India) Ltd. has convened an EGM on 16th Nov'26 to approve the divestment of its entire stake in Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), to HarmeeCare Pharmaceuticals. Prior to the sale, Kilitch will convert up to INR 57.00 crore of outstanding debt into KEB equity, raising its holding from 67.00% to 89.17%. The total transaction value is USD 14.00M, with Kilitch receiving USD 12.855M. Net proceeds will fund loan repayments, interest reduction, and expansion of its Pen manufacturing facility in India.

Original exchange filing (PDF)

More announcements from Kilitch Drugs India Ltd

All Kilitch Drugs India Ltd announcements